<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the in vitro effect on clonogenic potential (CFU-GM) and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) progenitors of an anti-oxidant (<z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi>, NAC) and/or a differentiating (<z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi>, ATRA) agent </plain></SENT>
<SENT sid="1" pm="."><plain>NAC significantly <z:mp ids='MP_0006043'>reduced apoptosis</z:mp>, both NAC and ATRA induced an increase in CFU-GM, but NAC seemed to be particularly effective in the high risk (HR) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>NAC + ATRA conferred a significant advantage in terms of CFU-GM with respect to NAC and ATRA alone </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> <z:mp ids='MP_0001651'>Necrosis</z:mp> Factor-alpha (TNF-alpha) levels decreased after incubation with NAC in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> samples </plain></SENT>
<SENT sid="4" pm="."><plain>This study shows that ineffective hemopoiesis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> could benefit from both NAC and ATRA, suggesting that anti-oxidant treatment may play a role in guaranteeing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cell survival, predisposing them towards differentiation </plain></SENT>
</text></document>